TPD | Jotup

Enhancing Treatments using Targeted Protein Degradation, Upcoming Webinar Hosted by Xtalks

Retrieved on:

星期一, 十二月 18, 2023

Drug discovery, UPD, Protein, Cancer, Agriculture, Autoimmunity, GenScript Biotech, TPD, POI, Proteostasis, Vaccine, Fine chemical, Biochemistry

TORONTO, Dec. 18, 2023 /PRNewswire-PRWeb/ -- Discover a webinar delving into targeted protein degradation (TPD), an approach using cellular machinery to selectively remove proteins, promising more effective treatments with minimized side effects. The main classical small molecule drug discovery strategies are inhibiting the biological function of proteins of interest, which either block the active pocket or change the protein conformation. However, the significant disadvantages such as limitations in target candidates, dose issues and quick resistance foundations, are calling for a more preferable therapy with fewer side effects.

Key Points:

In this free webinar, explore insights into targeted protein degradation (TPD) and learn new avenues for enhanced treatment efficacy through selective protein removal.
TORONTO, Dec. 18, 2023 /PRNewswire-PRWeb/ -- Discover a webinar delving into targeted protein degradation (TPD), an approach using cellular machinery to selectively remove proteins, promising more effective treatments with minimized side effects.
Join this webinar to explore insights into TPD and learn new avenues for enhanced treatment efficacy through selective protein removal.
Join Yongheng Huang, Doctor in Biochemistry, Protein Senior Scientist, GenScript , for the live webinar on Thursday, January 11, 2024, at 9am EST (3pm CET/EU-Central).

Black & Veatch Advances Green Hydrogen Production in Indonesia

Retrieved on:

星期二, 十一月 7, 2023

Black & Veatch , a global leader in critical infrastructure solutions, has conducted a feasibility study for Augustus Global Investment (AGI) on the generation of green hydrogen in Indonesia.

Key Points:

Black & Veatch , a global leader in critical infrastructure solutions, has conducted a feasibility study for Augustus Global Investment (AGI) on the generation of green hydrogen in Indonesia.
Black & Veatch provided a plant configuration and technology analysis and order-of-magnitude cost estimates for hydrogen generation and storage.
The proposed green hydrogen production plant would be built in the Arun Lhokseumawe Special Economic Zone (SEZ) in the Aceh province of Indonesia.
Black & Veatch is involved in building 245 MW of electrolysis capacity, nearly doubling green hydrogen production worldwide, including as the engineering, procurement and construction (EPC) provider for the Advanced Clean Energy Storage facility in Delta, Utah, USA, which will be among the world’s largest industrial green hydrogen production and storage facilities.

Kymera Therapeutics Announces Third Quarter 2023 Financial Results and Provides a Business Update

Retrieved on:

星期四, 十一月 2, 2023

ET

Key Points:

ET
WATERTOWN, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today reported financial results for the third quarter ended September 30, 2023, and provided business updates on its pipeline of protein degraders.
Collaboration Revenues: Collaboration revenues were $4.7 million for the third quarter of 2023 compared to $9.6 million for the third quarter of 2022.
Net Loss: Net loss was $52.9 million for the third quarter of 2023 compared to a net loss of $43.0 million for the third quarter of 2022.
Cash and Cash Equivalents: As of September 30, 2023, Kymera had $435 million in cash, cash equivalents, and investments.

C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Retrieved on:

星期三, 十一月 1, 2023

WATERTOWN, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today reported financial results for the third quarter ended September 30, 2023, as well as recent business highlights.

Key Points:

Revenue: Total revenue for the third quarter of 2023 was $11.1 million, compared to $6.8 million for the third quarter of 2022.
Research and Development (R&D) Expense: R&D expense for the third quarter of 2023 was $28.3 million, compared to $29.7 million for the third quarter of 2022.
Net Loss and Net Loss per Share: Net loss for the third quarter of 2023 was $27.0 million, compared to $32.0 million for the third quarter of 2022.
Net loss per share for the third quarter of 2023 was $0.55 compared to $0.65 for the third quarter of 2022.

SK Life Science Labs, a Subsidiary of SK Biopharmaceuticals, Presents Discovery of Oral SMARCA2 Degraders Data at 6th Annual Targeted Protein Degradation Summit

Retrieved on:

星期二, 十月 31, 2023

Therapy, SMARCA4, Cancer, SMARCA2, TDP, TPD, Growth, ID, Lung cancer, Fine chemical

KOREA and KING OF PRUSSIA, Pa., Oct. 31, 2023 (GLOBE NEWSWIRE) -- SK Life Science Labs (formerly Proteovant Therapeutics) a subsidiary of SK Biopharmaceuticals, today will present preclinical data supporting its SMARCA protein degradation discovery program at the 6th Annual Targeted Protein Degradation (TPD) Summit.

Key Points:

KOREA and KING OF PRUSSIA, Pa., Oct. 31, 2023 (GLOBE NEWSWIRE) -- SK Life Science Labs (formerly Proteovant Therapeutics) a subsidiary of SK Biopharmaceuticals, today will present preclinical data supporting its SMARCA protein degradation discovery program at the 6th Annual Targeted Protein Degradation (TPD) Summit.
SK Life Science Labs integrates its AI-enabled target ID platform, protein degrader discovery and development expertise, and MOPED™ molecular glue screening platform to identify and advance novel protein degraders.
“Today’s presentation unveils new data that showcase SK Life Science Labs’ unique approach to discovering compounds with the potential to change the future of cancer therapeutics,” said Donghoon Lee, President and CEO of SK Biopharmaceuticals, SK Life Science Inc., and SK Life Science Labs.
“Since acquiring SK Life Science Labs earlier this year, we have been focused on leveraging the company’s R&D capabilities and supporting its promising programs.

Kymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating $40 Million Payment from Sanofi

Retrieved on:

星期五, 十月 27, 2023

Mevalonate pathway, AD, Inflammation, International development, Doctor of Philosophy, Protein, TPD, Pharmacokinetics, Hidradenitis suppurativa, Sanofi, Safety, Therapy, Patient, Pharmaceutical industry, HS, MD, IRAK4

The Phase 2 study will evaluate the efficacy, safety, pharmacokinetics, and biological effects of KT-474 compared with placebo in adult patients with moderate to severe HS.

Key Points:

The Phase 2 study will evaluate the efficacy, safety, pharmacokinetics, and biological effects of KT-474 compared with placebo in adult patients with moderate to severe HS.
Kymera’s partner Sanofi is conducting the Phase 2 study in HS, and has initiated a second randomized Phase 2 trial in AD.
Under the terms of the collaboration, dosing of the first patient in the HS trial generated a milestone payment of $40 million.
Dosing of the first patient in the AD trial will also generate a milestone payment to Kymera.

SEED Therapeutics Discloses Novel Molecular Glue IND Candidate for Cancer at “Targeted Protein Degradation Think Tank” Symposium

Retrieved on:

星期四, 十月 26, 2023

SEED is a subsidiary of BeyondSpring, Inc. (NASDAQ: BYSI), a clinical-stage biopharmaceutical company focusing on developing innovative therapies.

Key Points:

SEED is a subsidiary of BeyondSpring, Inc. (NASDAQ: BYSI), a clinical-stage biopharmaceutical company focusing on developing innovative therapies.
According to Dr. Huang, “The SEED TPD Think Tank shared key TPD developments across academia and industry.
Their research, insight, and conviction allow SEED to focus and accelerate basic research into a fast-expanding TPD drug pipeline, enabled by our unique ability to identify the right E3.
This symposium provided a valuable exchange on new directions, opportunities, and challenges on TPD drug development.

Snowplus Redefines Disposable Vaping with New 5,000 Puff E-Cigarettes

Retrieved on:

星期四, 十月 26, 2023

FDA, Gold bar, Certification, Gold, TPD, Sequoia Capital, CLIC, Tobacco

BIRMINGHAM, England, Oct. 26, 2023 /PRNewswire/ -- Snowplus, the world's leading independent vape brand, has launched two all-new disposable e-cigarettes – the Snowplus Gold Bar and Snowplus Clic – featuring an industry-first 5,000 puffs TPD-compliant device. Debuting at the UK Vaper Expo from October 27-29 in Birmingham, the new products represent a pioneering innovation in the vaping market.

Key Points:

BIRMINGHAM, England, Oct. 26, 2023 /PRNewswire/ -- Snowplus, the world's leading independent vape brand, has launched two all-new disposable e-cigarettes – the Snowplus Gold Bar and Snowplus Clic – featuring an industry-first 5,000 puffs TPD-compliant device.
"The Snowplus Gold Bar will be the game-changer in the industry, it will definitely lead the product development direction," said a Snowplus spokesperson.
Most legal disposable vaping products in the UK deliver less than 800 puffs to meet TPD.
Engineered with innovative structures and improved atomization, Snowplus is the first to achieve such high puff counts in a TPD-compliant vape.

Foghorn Therapeutics to Present at Upcoming Conferences Including New Preclinical Data from EP300 and CBP Selective Degrader Programs

Retrieved on:

星期二, 十月 24, 2023

EP300, Drug discovery, Land, Chair, TPD, Biology, CBP, Annual general meeting, Foghorn, Therapy, Gene expression, Pharmaceutical industry, Management

The TPD Summit will be held October 30–November 2 in Boston, Massachusetts, and CTOS will be held November 1–4 in Dublin, Ireland.

Key Points:

The TPD Summit will be held October 30–November 2 in Boston, Massachusetts, and CTOS will be held November 1–4 in Dublin, Ireland.
Foghorn will participate in multiple sessions, including a keynote presentation by Steve Bellon, Foghorn’s Chief Scientific Officer, where data from its selective EP300 and CBP degrader programs will be presented.
Danette Daniels, Foghorn’s Vice President, Protein Degradation Platform, will provide the conference’s opening remarks as the Chair.
Presenter: Laura La Bonte, Senior Director, Biology & Research Portfolio Strategy, Foghorn Therapeutics

Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of MDM2 Degraders in Acute Myeloid Leukemia and Merkel Cell Carcinoma

Retrieved on:

星期一, 十月 16, 2023

WATERTOWN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, reported preclinical data highlighting the therapeutic potential in liquid and solid tumors of potent and selective heterobifunctional degraders of MDM2, including KT-253. The data was presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics on October 11-15, 2023, in Boston, Massachusetts and will also be shared at the 10th International MDM2 Workshop taking place October 15-18, 2023, in Tokyo, Japan.

Key Points:

p53 remains intact (wild type) in approximately 50% of cancers, meaning that it retains its ability to modulate cancer cell growth.
In preclinical studies, MDM2 degraders have demonstrated the ability to overcome the MDM2 feedback loop observed with MDM2 SMIs and rapidly induce cell death in sensitive p53 wild-type cancer cell lines, even with brief compound exposure.
This may enable an improved therapeutic index, which could result in a superior efficacy and safety profile over MDM2 SMIs.
These data demonstrate in vitro efficacy of an MDM2 degrader, KTX-049, against p53 wild-type MCC cell lines that was achieved with brief compound exposure.